Literature DB >> 1664828

Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.

E Vallée1, E Azoulay-Dupuis, J J Pocidalo, E Bergogne-Bérézin.   

Abstract

We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung. After a single subcutaneous injection, bioactivities were determined concomitantly in non-infected and infected animals, at a time at which pneumonia was well developed. Fluoroquinolones exhibited generally good activity at the site of infection. Infection did not affect the tissue distribution of either drug. However, the differences observed in non-infected controls (greater AUCs and longer half-lives of temafloxacin and sparfloxacin in lung and serum) were accentuated in infected mice, with probable trapping of temafloxacin and sparfloxacin at the site of infection and more persistent activity in the lung. These data suggest that the anti-pneumococcal activity of temafloxacin, and to a lesser extent sparfloxacin, were greatly favoured by their pharmacokinetic behaviour in the infected lung.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664828     DOI: 10.1093/jac/28.suppl_c.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Antibiotic penetration into lung tissues.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

2.  Penetration of meropenem in lung, bronchial mucosa, and pleural tissues.

Authors:  B Byl; F Jacobs; I Roucloux; P de Franquen; M Cappello; J P Thys
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

3.  Assessment of antibiotic levels in lung tissue with erosion-controlled dosage forms.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.569

Review 4.  Quinolones in the treatment of lower respiratory tract infections in adult patients.

Authors:  C Carbon
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Activity of quinolones against gram-positive cocci: clinical features.

Authors:  H Giamarellou
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.

Authors:  Seth T Housman; Jared L Crandon; Wright W Nichols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

7.  Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.

Authors:  C Chidiac; M Roussel-Delvallez; B Guery; G Beaucaire
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

8.  Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  A Cagni; C Chuard; P E Vaudaux; J Schrenzel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.